CDK-TCIP2
DK-TCIP2, linking inhibitor of CDK9 SNS-032 with ligands of BCL6 BI-3812 (HY-111381), is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer[1].
Product Specifications
UNSPSC
12352005
Target
BCL6; CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk-tcip2.html
Purity
98.94
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C(OCC(NC)=O)=CC2=C(N1C)C(OC)=CC(NC3=NC(N4CCC(CC4)C(N5CCC6(CCN(C(CN7CCC(CC7)C(NC8=NC=C(SCC9=NC=C(C(C)(C)C)O9)S8)=O)=O)CC6)CC5)=O)=NC=C3Cl)=C2
Molecular Formula
C52H67ClN12O8S2
Molecular Weight
1087.75
References & Citations
[1]Sarott RC, et al. Relocalizing transcriptional kinases to activate apoptosis. Science. 2024 Oct 4;386 (6717) :eadl5361.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human IgG (Immunoglobulin Gamma Heavy Chain) (B-Cell Marker) (IG1707R), CF488A conjugate, 0.1mg/mL
![Osteoprotegerin Mouse Monoclonal Antibody [9C1]](https://cdn.genprice.uk/products/992/68dd1c8b061270361ea816b6/imageurl/em1701-98.webp)
